Table 2. Summary of the results of the included studies.
| Outcome | Akhtari et al (2014)14 | Souza et al (2016)11 | Guazzelli et al (2014)13 | Postigo et al (2016)12 | Vale et al (2018)10 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary outcomes (Final mean (SD)) | ||||||||||||
| Tribulus | Placebo | Tribulus | Placebo | Tribulus | Placebo | Tibolone | Tribulus | Placebo | Tribulus | Placebo | ||
| Health-related quality of life | NA | NA | NA | NA | NA | |||||||
| Sexual function assessed by FSFI (total score) | 26.80 (3.03)* | 22.41 (2.87) | 25.8† | 22.93† | NA | NA | 25.27† | 20.29† | ||||
| Sexual function assessed by: FSFI (sub scores) | Desire | 3.09 (0.71) | 2.86 (0.79) | 3.66† | 3.15† | 3.24† | 2.88† | |||||
| Arousal | 4.21 (0.67)* | 3.17 (0.75) | 3.74† | 3.04† | 3.27† | 3.08† | ||||||
| Lubrication | 4.66 (0.87)* | 4.18 (0.79) | 4.62† | 4.39† | 3.98† | 3.38† | ||||||
| Orgasm | 4.20 (0.72)* | 3.59 (0.85) | 4.12† | 3.83† | 3.84† | 3.24† | ||||||
| Satisfaction | 4.61 (0.93)* | 3.75 (1.12) | 4.66† | 4.03† | 4.36† | 3.34† | ||||||
| Pain | 5.07 (1.01) | 4.87 (1.42) | 5.0† | 4.5† | 4.58† | 4.38† | ||||||
| Sexual function assessed by SQ-F (total score) | NA | NA | 69† | 56† | 84† | 70.9 (17.6) | 56.6 (17.9) | Results were reported based on the presence of sexual dysfunction (%) | ||||
| Serious adverse events | No cases | NA | NA | NA | ||||||||
| Secondary outcomes (Final mean (SD) | ||||||||||||
| Serum testosterone levels assessed by: serum total testosterone level | NA | 14.2 (6.9) | 11.7 (6.2) | NA | 20.5 (9.7)* | 13.9 (10.7) | ||||||
| Minor adverse events | One patient reported abdominal cramps (not reported in which group) | NA | NA | NA | ||||||||
Abbreviations: FSFI, Female Sexual Function Index; NA, not assessed; SD, standard deviation; SQ-F, Sexual Quotient Female Version.
*
Statistically significant difference.
†
Standard deviations were not reported.